Neuphoria Therapeutics (NEUP) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Neuphoria Therapeutics (NEUP) is Strong Underperform.

The composite score behind that read is -0.51, weighing +0.00 of bullish evidence against -0.50 bearish.

Neuphoria Therapeutics last closed at $3.45, -0.58% on the session.

Against the IVW growth benchmark the position is -1.50% over the forecast window.

The read is built from 12 underlying insights — 0 bullish and 12 bearish.

Agreement across those insights is 100%.

16 graded predictions for NEUP so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Neuphoria Therapeutics in the 17th percentile on return on equity, where 100 is best.

Neuphoria Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $18.78M.

StockMap tracks Neuphoria Therapeutics as the 304th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite Neuphoria Therapeutics ranks 335th of 344 in the group, against a group median of -0.21.